Partnering for Targeted Delivery
A modular, plug-and-play polymeric nanoparticle platform enabling precise in vivo gene delivery across therapeutic areas
Expanding what delivery can enable
Beyond our internal in vivo CAR-T programs, Alaya.bio’s targeting polymeric nanoparticle platform is designed to support collaborative development across multiple disease areas.
We partner with biotech and pharmaceutical companies seeking to deliver genetic payloads to specific cells and tissues with precision, scalability, and translational readiness.
Our role is clear:
To enable your biology with a delivery system engineered for in vivo performance.
Our platform value pillars
A modular, plug-and-play platform built for rapid indication expansion.
Alaya.bio’s platform has a modular architecture with three independently exchangeable components. Partners can plug their therapeutic innovations into a delivery technology that has already been validated.
Targeting Ligand
We can direct the nanoparticle to any cell type by changing the surface targeting agent. The same platform can graft one or two different targeting moieties to better address tissue-specific delivery. The polymer chemistry remains unchanged. Only the targeting moiety changes.
Therapeutic payload
The lentiviral vector core can carry any transgene. Proprietary CAR designs, optimized signaling domains, and next-generation constructs all plug directly into our delivery platform.
Expression Mode
The lentiviral vector can be configured for either integrative delivery (permanent gene expression, suited to durable oncology responses) or non-integrative episomal delivery (transient expression, suited to autoimmune and other indications where permanence is not required). The same nanoparticle formulation supports both.
What we offer partners
We provide more than access to technology. We offer a structured path to clinical translation.
A configurable in vivo delivery platform adaptable to your target and indication
Accelerated timelines by leveraging an existing platform infrastructure
Collaborative R&D support across nanoparticle design, formulation, and in vivo validation
A leadership team experienced in scientific partnerships and translational development
Flexible deal structures
Let’s Explore a Targeted Delivery Strategy
If you are developing a genetic payload or immune-modulating therapy and seeking scalable in vivo delivery, we welcome the opportunity to discuss collaboration.